

EMLc		Codes ATC: J01XD01 A01AB17
Indication	Necrotising fasciitis	Code ICD11: 1B71.Z
INN	Metronidazole	
Type de médicament	Chemical agent	
Groupes d'antibiotiques	A ACCESS	
Type de liste	Liste de base (EML) (EMLc)	
Formulations	Oral > Liquid: 200 mg per 5 mL (as benzoate) Local > Rectal > Suppository: 1 g suppository (EML) ; 500 mg suppository (EML) Parenteral > General injections > unspecified: 500 mg per 100 mL in vial Injection Oral > Solid > tablet: 200 mg ; 250 mg ; 400 mg ; 500 mg	
Historique des statuts LME	Ajouté pour la première fois en 2021 (TRS 1035) Modifié en 2023 (TRS 1049)	
Sexe	Tous	
Âge	Aussi recommandé pour les enfants	
Équivalence thérapeutique	La recommandation concerne ce médicament spécifique	
Renseignements sur le brevet	Patents have expired in most jurisdictions Lire la suite sur les brevets. 	
Wikipédia	Metronidazole 	
DrugBank	Metronidazole 	

Recommandation du comité d'experts

In consideration of the review of the age appropriateness of formulations of medicines on the EMLc, and the comparison report of the EML versus EMLc, the Expert Committee recommended changes to the EMLc for addition of new, age-appropriate formulations and strengths of existing essential medicines, deletion of unavailable or age-inappropriate formulations and strengths, and other listing modifications as proposed in the application. The Committee also endorsed the proposals for further review of the public health relevance and evidence for specific medicines for use in children for potential future consideration for inclusion on the EMLc. The Committee noted and welcomed the ongoing review being coordinated by the Secretariat for the remaining sections of the EMLc for consideration by the 2025 Expert Committee. As a result of the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - replacing the oral liquid formulation of clindamycin (oral liquid 75 mg/5 mL) with powder for oral liquid 75 mg/5 mL (as palmitate hydrochloride) on the EML and EMLc - the addition of a new strength formulation of ceftriaxone (powder for injection: 500 mg (as sodium) in vial) to the EML and EMLc. - the range of strengths of metronidazole tablets be replaced with reference to specific strengths on the EML and EMLc. - the addition of new strength formulations of IV vancomycin (500 mg, 1 g (as hydrochloride) on the EMLc.

Recommandations de la LME : Necrotising fasciitis

Premier choix

Second choix

metronidazole

co-prescrire avec [ceftriaxone](#)

clindamycin

co-prescrire avec [piperacillin + tazobactam](#)

vancomycin

